A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Kleiner Device Labs Presents e-Poster at Southern Neurosurgical Society Meeting

Meeting: "Rethinking Posterior MIS Fusion – Enabling Risk Reduction in Posterior Spinal Surgery"

Kleiner Device Labs (KDL) today announced that an e-Poster has been accepted for the Southern Neurosurgical Society’s 2024 annual conference beginning on March 7 in Orlando.  The e-Poster (#156) highlights research results of new innovations in lumbar spinal implant and grafting technologies to reduce risks from poor/insufficient graft volume and placement, surgical site infection (SSI), collateral tissue damage due to multiple instrument passes, and from extended OR time.  

Posterior approach spine fusion has a number of inherent risks to patients’ health and successful outcomes, as well assignificant frustrations for surgeons, and those became the key objectives of our re-engineering a complete interbody system,said Jeff Kleiner, MD, founder and CEO of KDL.  

Dr. Blake Burkert, of NeuroSpine Group, Eugene, Oregon, noted, I share those concerns and want to minimize risks in my own OR.  Utilizing the new system over the past year has proven to be an effective answer for my PLIF and TLIF procedures and has transformed my thinking on the posterior approach to treating spine conditions.

The company will attend the meeting and looks forward to demonstrating the new KG®2 Surge® flow-thru interbody system to surgeons. The first 50 cases with the new KG 2 Surge demonstrated an average of 10ml of bone graft delivered per disc space and an average of 8 minutes total elapsed time for trial, cage placement, grafting and release of the implant.  

The e-Poster presentation will be available at the meting and afterwards on the company’s web site.

For KG2 videos and information, please go to the company’sweb site.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy